ConditionsCerebral Small Vessel DiseasesCadasilHTRA1-Related Autosomal Dominant Cerebral AngiopathyCOL4A1-Related Brain Small Vessel Disease With HaemorrhageFabry DiseaseMagnetic Resonance ImagingNext-generation SequencingStroke
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNational Taiwan University Hospital
About this trial
The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.
Eligibility criteria
Qualifiers
stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ICH or young stroke)
cognitive impairment or dementia
gait disturbance
parkinsonism (especially vascular parkinsonism features)
Disqualifiers
MRI evidence of CSVD due to other inflammatory, malignancy, or structural lesions
patients or family members not willing to sign informed consent
Trial design
Treatments tested in this trial
- MRI
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov